A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06882961 In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs PF-06882961 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 06 Nov 2017 Planned End Date changed from 7 Feb 2018 to 19 Jan 2018.
- 06 Nov 2017 Planned primary completion date changed from 7 Feb 2018 to 19 Jan 2018.
- 06 Nov 2017 Status changed from not yet recruiting to recruiting.